Idera Pharma: ASH 2015 (Idera Pharmaceuticals, Inc) - Dec 19, 2015 - “Safety: IMO-8400 was generally well tolerated at dose levels of 0.6, 1.2 and 2.4 mg/kg (1.2 mg/kg twice) per week, The Maximum Tolerated Dose of IMO-8400 has not yet been identified”; “Clinical activity: In the highest dose cohort studied to date (2.4 mg/kg): There were 3 responses and 2 stable disease out of 6 patients with evaluable disease treated to date, Median time to first response ~10.5 weeks, Improvements in symptoms, hemoglobin and bone marrow were seen, One of these responders was refractory to ibrutinib”; “Summary: These data in patients with WM provide the first clinical evidence supporting inhibition of the TLR pathway as a potential therapeutic approach for B-cell lymphomas harboring the MYD88 L265P oncogenic mutation”
P1/2 data • Oncology
|